ASCO 2026 showcases multiple cancer therapy breakthroughs

Several late‑stage clinical trials presented at the 2026 American Society of Clinical Oncology (ASCO) meeting reported notable advances across a range of cancers.

A personalized mRNA vaccine (intismeran) combined with pembrolizumab (Keytruda) cut the five‑year recurrence risk for high‑risk melanoma by 49%, with 68.8% of patients remaining disease‑free versus 49.1% on immunotherapy alone.

In head‑and‑neck cancer, the bispecific antibody amivantamab achieved tumour reduction or complete disappearance in 43 of 102 heavily pre‑treated patients, according to the international study presented by Italian investigators.

For unresectable hepatocellular carcinoma, the “Stride” regimen of durvalumab plus tremelimumab together with lenvatinib and trans‑arterial chemo‑embolisation (TACE) lowered the risk of disease progression by 30% and extended median progression‑free survival to 13.0 months versus 9.8 months with TACE alone.

A novel oral Ras inhibitor, daraxonrasib, doubled median overall survival in metastatic pancreatic ductal adenocarcinoma to 13.2 months, compared with 6.6 months on standard chemotherapy, while also reducing severe side‑effects.

Separate reports highlighted Cuba’s HEBERSaVax therapeutic cancer vaccine, which showed encouraging safety and activity in early‑phase trials, and a Spanish research team that repurposed measles‑vaccine‑induced immunity to target tumour cells. A commentary noted China’s rising share of early‑phase oncology trials, signaling a shift in global drug‑development leadership.

Collectively, these data suggest a wave of new immunotherapy‑based options that could reshape treatment standards for melanoma, head‑and‑neck, liver, pancreatic and other solid tumours.